Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Sean Turman"'
Autor:
Sean Turman, Benjamin Kemp, Ronald Herbst, Janet Griffiths, Jennifer Cann, Mary Jane Hinrichs, M. Jack Borrok, Lisa Marie Kitching Vinall, D. Gareth Rees, David Howe, Yue Wang, Carlos Gonzalez, Shu Wang, Steven Eck, Hong Sun, Brian Naiman, Katherine A. Vousden, Koshu Okubo, Roland Kolbeck, Antonio DiGiandomenico, Tanya N. Mayadas, Gary P. Sims, Ethan Grant, Neang Ly, Ximing Xiong, Yebin Zhou, Srinath Kasturiangan, Holly Koelkebeck, Weiguang Zhao, Christopher Morehouse, Bo Chen
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveImmune complexes (ICs) play a critical role in the pathology of autoimmune diseases. The aim of this study was to generate and characterise a first-in-class anti-FcγRIIA antibody (Ab) VIB9600 (previously known as MEDI9600) that blocks IgG i
Publikováno v:
Molecular Immunology. 85:57-65
Recent studies have demonstrated the importance of CD47 in protecting malignant B cells from antibody dependent cellular phagocytosis (ADCP). Combined treatment of anti-CD47 and -CD20 antibodies synergistically augment elimination of tumor B cells in
Autor:
Isharat Yusuf, Ronald Herbst, Tom M. McCaughtry, Roland Kolbeck, Hong Sun, Sean Turman, Yue Wang, Sandra Gallagher
Publikováno v:
Arthritis & Rheumatology. 68:965-976
Objective To evaluate treatment with MEDI-551, a humanized anti-human CD19 monoclonal antibody, in a model of autoimmunity involving mice transgenic (Tg) for Sle1 and human CD19 (hCD19). Methods Sle1.hCD19-Tg mice were given either a single intraveno
Publikováno v:
Cancer Research. 80:5178-5178
CD40 stimulation on antigen-presenting cells (APCs) promotes activation of CD8(+) cytotoxic T cells and several CD40 agonistic antibodies have shown promising anti-tumor activities in initial clinical trials. However, agonistic CD40 stimulation also
Publikováno v:
Cancer Research. 80:2267-2267
Background: While diverse strategies may boost anti-tumor immunity, of significant interest are therapeutic approaches that are efficacious in tumors with high and low immune cell infiltration. Targeting CD40 with its natural ligand (CD40L) augments
Autor:
Jane Connor, Sean Turman, Payal Mehta, Roland Kolbeck, Ling-Ling An, Brian Naiman, Michael Fung, Linda Xu, Miguel A. Sanjuan, Thornik Reimer
Publikováno v:
European Journal of Immunology. 44:3669-3679
Anaphylatoxin C5a released upon complement activation is associated with both acute and chronic inflammations such as gout. The pathogenesis of gout was identified as uric acid crystal deposition in the joints that activates inflammasome, leading to
Autor:
Shu Wang, Roland Kolbeck, Ronald Herbst, Benjamin Kemp, Gary P. Sims, Steven Eck, Sean Turman, Ximing Xiong, Bo Chen, D. Close, Katherine A. Vousden, S Kasturiangan, Antonio DiGiandomenico, Mary Jane Hinrichs, Hong Sun, Lisa Marie Kitching Vinall, Janet Griffiths, Ethan Grant
Publikováno v:
Oral Presentations.
Background Collectively, the cell surface Fc region of IgG receptors (FcγRs) engage soluble IgG and IgG containing immune complexes and trigger activation or inhibtory signals that play a critical role in the regulation of immune responses. The low
Publikováno v:
Cancer Research. 79:1534-1534
Targeting CD40 with its natural ligand (CD40L) enhances the immune-stimulatory functions of dendritic cells, B cells, monocytes and macrophages, resulting in T cell priming, expansion and differentiation. Thus, activation of the CD40 pathway is an at
Autor:
Isharat Yusuf, Lorin Roskos, Ronald Herbst, Yuling Wu, Yue Wang, Sandra Gallagher, Sean Turman, Ahmad Akhgar
Publikováno v:
International immunopharmacology. 36
B cell depletion therapy is beneficial for patients with B cell malignancies and autoimmune diseases. CD19, a transmembrane protein, is expressed on a vast majority of normal and neoplastic B cells, making it a suitable target for monoclonal antibody
Autor:
Sandra, Gallagher, Isharat, Yusuf, Tom M, McCaughtry, Sean, Turman, Hong, Sun, Roland, Kolbeck, Ronald, Herbst, Yue, Wang
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.). 68(4)
To evaluate treatment with MEDI-551, a humanized anti-human CD19 monoclonal antibody, in a model of autoimmunity involving mice transgenic (Tg) for Sle1 and human CD19 (hCD19).Sle1.hCD19-Tg mice were given either a single intravenous dose of MEDI-551